Journal article
Doni Bloomfield, Bryan S. Walsh, Aaron S. Kesselheim
JAMA Internal Medicine, vol. 182(3), 2022, pp. 245-246
JAMA Internal Medicine, vol. 182(3), 2022, pp. 245-246
Semantic Scholar
DOI
PubMed
Cite
Cite
APA
Click to copy
Bloomfield, D., Walsh, B. S., & Kesselheim, A. S. (2022). Extending Drug Monopolies by Patenting Safe Drug Use. JAMA Internal Medicine, 182(3), 245–246. https://doi.org/10.1001/jamainternmed.2021.7954
Chicago/Turabian
Click to copy
Bloomfield, Doni, Bryan S. Walsh, and Aaron S. Kesselheim. “Extending Drug Monopolies by Patenting Safe Drug Use.” JAMA Internal Medicine 182, no. 3 (2022): 245–246.
MLA
Click to copy
Bloomfield, Doni, et al. “Extending Drug Monopolies by Patenting Safe Drug Use.” JAMA Internal Medicine, vol. 182, no. 3, 2022, pp. 245–46, doi:10.1001/jamainternmed.2021.7954.
BibTeX Click to copy
@article{doni2022a,
title = {Extending Drug Monopolies by Patenting Safe Drug Use},
year = {2022},
issue = {3},
journal = {JAMA Internal Medicine},
pages = {245-246},
volume = {182},
doi = {10.1001/jamainternmed.2021.7954},
author = {Bloomfield, Doni and Walsh, Bryan S. and Kesselheim, Aaron S.}
}
Summary:
We uncover a new strategy pharmaceutical companies are using to extend monopoly rights over old medicines: patenting safe methods of using their drugs. After discussing several costly examples of this strategy, we close with steps Congress and executive agencies can take to address it.
We uncover a new strategy pharmaceutical companies are using to extend monopoly rights over old medicines: patenting safe methods of using their drugs. After discussing several costly examples of this strategy, we close with steps Congress and executive agencies can take to address it.
